Literature DB >> 10494848

Processing of artificial peptide-DNA-conjugates by the mitochondrial intermediate peptidase (MIP).

M Seibel1, C Bachmann, J Schmiedel, N Wilken, F Wilde, H Reichmann, G Isaya, P Seibel, D Pfeiler.   

Abstract

Import of DNA from the cytoplasm into the mitochondrial matrix is an obligatory step for an in organello site-directed mutagenesis or gene therapy approach on mitochondrial DNA diseases. In this context, we have developed an artificial DNA translocation vector that is composed of the mitochondrial signal peptide of the ornithine transcarbamylase (OTC) and a DNA moiety. While this vector is capable of directing attached passenger molecules to the mitochondrial matrix, the recognition of this artificial molecule by the endogenous mitochondrial signal peptide processing machinery as well as the cleavage of the peptide plays a pivotal role in the release of the attached DNA. To study the proteolytic processing of the artificial vector, various signal peptide-DNA-conjugates were treated with purified mitochondrial intermediate peptidase. When the leader peptide is directly linked to the DNA moiety without an intervening spacer, MIP processing is prevented. Cleavage of the peptide can be restored, however, when the first ten amino acid residues of the mature part of OTC are appended at the carboxy-terminal end of the signal peptide. Our results show that artificial peptide-DNA-conjugates are recognized by the mitochondrial proteolytic machinery, and therefore an interference of the peptide with the DNA function can be excluded.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494848     DOI: 10.1515/BC.1999.119

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  3 in total

Review 1.  Delivery of drugs and macromolecules to mitochondria.

Authors:  Abhijit Mukhopadhyay; Henry Weiner
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

Review 2.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

3.  Production of homoplasmic xenomitochondrial mice.

Authors:  Matthew McKenzie; Ian A Trounce; Carolyn A Cassar; Carl A Pinkert
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.